HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enforce Immediately In CBD Supplement Market, Industry Groups Suggest To FDA

Executive Summary

FDA should go beyond warning letters to carry out inspections, import reviews and other actions on companies marketing CBD-containing supplements and foods, CHPA says. It and other consumer health trade groups urge agency to act immediately numerous businesses marketing products that could threaten public health.

You may also be interested in...



New Report, Same Theme On US FDA's Policy On Cannabidiols: ‘Extensive Data Gaps’ On Safety

FDA’s second report to Congress on oversight of CBD market includes results from studies of whether products are mislabeled or adulterated, but also indicates throughout that more data are needed on safety of hemp-derived CBD ingredients used in myriad consumer health, cosmetic and food products already available.

US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements

As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.

HBW Market News: CHPA Petitions For CBD Reg, PEW Urges Stronger Supplement Oversight

AHPA releases guidance for tea and infusion products on regulatory and liability implications as a result of increasing Prop 65 lawsuits; CHPA files citizen petition urging FDA to act on a CBD pathway; PEW pushes for stronger supplement oversight; and more.

Related Content

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel